Supporting Information: Previous studies that reported the relationship between cancers/tumors and top most feasible drug canridate compounds selected for ALK, ELGN3 and NUAK1

This compound was reported to target 3phosphoinositide dependent protein kinase-1 (PDPK1 or PDK1) [1, 2]. PDK1 was reported to be cancer-related therapeutic target gene [3]. This compound was also included in National Cancer Institute Drug Dictonray (NCIDD) that says “A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis.” 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine (DB08700) this compound was reported to target ALK, LCK, c-MET, TRKA, TRKB, TIE2 and ABL [4]. Hepatocyte growth factor receptor (c-MET) was also reported to be targeted by this compound in an addtional report [5]. c-MET was reported to be cancerrelated therapeutic target gene [6]. LCK [4] that was reported to a tumor antigen [7]. TRKA and TRKB are receptors of Trk kinase whose inhibition was reported to be as new treatments for cancer and pain [8]. Targeting the TIE2 was reported to inhibit tumor growth and metastasis [9]. Activation of Abl Tyrosine Kinases was reported to promote invasion of aggressive breast cancer cells [10].